Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Xencor, Inc.

Market Cap 948M 817M 752M 707M 1.33B 89.42B 1.34B 8.91B 3.47B 43.89B 3.56B 3.48B 152B P/E 2026 *
-3.31x
P/E 2027 * -3.95x
Enterprise Value 948M 817M 752M 707M 1.33B 89.42B 1.34B 8.91B 3.47B 43.89B 3.56B 3.48B 152B EV / Sales 2026 *
13x
EV / Sales 2027 * 8.58x
Free-Float
98.82%
Yield 2026 *
-
Yield 2027 * -
1 day+4.75%
1 week+8.03%
Current month+7.58%
1 month+13.90%
3 months+8.86%
6 months-19.11%
Current year-16.53%
1 week 11.9
Extreme 11.9
13.26
1 month 10.38
Extreme 10.375
13.26
Current year 10.38
Extreme 10.375
15.4
1 year 6.92
Extreme 6.92
18.69
3 years 6.92
Extreme 6.92
27.24
5 years 6.92
Extreme 6.92
43.61
10 years 6.92
Extreme 6.92
58.34
Manager TitleAgeSince
Chief Executive Officer 55 31/01/2005
Director of Finance/CFO 48 08/04/2024
Chief Tech/Sci/R&D Officer 61 30/09/2006
Director TitleAgeSince
Director/Board Member 55 31/07/1997
Director/Board Member 58 24/07/2014
Director/Board Member 72 17/03/2015
Date Insider Type Main position Quantity % Market Cap.
04-09Sell

Chief Financial Officer

3,499 0.0048%
03-04Sell

General Counsel

5,011 0.0068%
03-04Sell

Chief Technology Officer

6,620 0.0090%
Change 5-day change 1-year change 3-year change Capi.($)
+4.75%+8.03%+53.79%-51.76% 948M
+3.23%+2.25%+65.02%+113.87% 56.24B
+0.04%+1.20%+47.67%+36.75% 43.76B
+3.04%+7.05%-12.15%-18.06% 23.32B
+3.07%+7.15%-1.82%+392.25% 21.34B
+2.75%+2.67%+23.70%-34.18% 15.75B
+5.27%+1.87%+13.67%-38.81% 15.6B
+0.65%-0.27%+26.80%+174.70% 13.18B
+2.23%+4.61%+20.43% - 12.01B
+1.92%+2.43%+112.68%+232.59% 11.87B
Average +2.72%+3.64%+34.98%+89.71% 21.4B
Weighted average by Cap. +2.39%+2.98%+37.35%+98.18%

Financials

2026 *2027 *
Net sales 73.03M 63M 57.93M 54.52M 102M 6.89B 103M 686M 267M 3.38B 274M 268M 11.7B 110M 95.28M 87.6M 82.45M 155M 10.42B 156M 1.04B 404M 5.12B 415M 406M 17.7B
Net income -307M -265M -243M -229M -430M -28.95B -434M -2.88B -1.12B -14.21B -1.15B -1.13B -49.16B -288M -248M -228M -215M -404M -27.17B -407M -2.71B -1.05B -13.33B -1.08B -1.06B -46.13B
Net Debt - -
Logo Xencor, Inc.
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Employees
260
Date Price Change Volume
17/06/26 12.78 $ +4.75% 1,051,847
16/06/26 12.20 $ -0.08% 871,478
15/06/26 12.21 $ -0.97% 638,904
12/06/26 12.33 $ +1.99% 591,563
11/06/26 12.09 $ +2.20% 500,334
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
12.78USD
Average target price
28.50USD
Spread / Average Target
+123.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. XNCR Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!